12-Apr-2011 - Medicago, Inc.

Medicago announces research collaboration for the development of a non-influenza vaccine candidate

Medicago Inc. announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.

Under the terms of the research collaboration, Medicago will apply its transient expression system to develop a vaccine candidate for a non-disclosed target. Medicago is eligible to receive payments on achievement of specified milestones stipulated in the contract.

"We believe this collaboration represents an important validation of our scientific leadership in vaccines," said Andy Sheldon, President and CEO of Medicago. "The combination of our rapid, efficacious and cost-effective VLP vaccine technology with such an accomplished partner allows us to further demonstrate the capability of our vaccine platform and has the potential to lead to further collaborations."

Facts, background information, dossiers
More about Medicago
  • News

    Medicago to build $245M production facility in Quebec City

    Medicago announced that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago's Quebec City office and laboratories. The project is expected to generate ... more

    Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology

    Medicago Inc.  and Cellectis plant sciences, a subsidiary of Cellectis SA announced the signing of a research agreement under which Medicago and Cellectis will collaborate to improve therapeutic proteins expressed from tobacco leaves. "We look forward to working with Cellectis plant science ... more

    Medicago announces an extension of its agreement with Genopole biopark

    Medicago Inc. announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense. This laborator ... more

  • Companies

    Medicago, Inc.

    Medicago is a publicly-traded biotechnology company focused on the development, production and commercialization of protein-based vaccines and biopharmaceuticals using a proprietary manufacturing system developed from its expertise in the genetic engineering of plants. more

    Medicago AB

    To be a trusted partner in the development and manufacture of critical bioreagents. To be committed to innovative solutions through excellence in research and development. To deliver highest level of quality products and world class services to our customers. To focus on broadering our rang ... more